Publication | Closed Access

Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection

VaccinationNovel Therapeutic VaccineVaccine DevelopmentViral HepatitisImmunologyHepatitis BHepatitisCore AntigenCpg OligodeoxynucletidesVaccine DesignPolyvalent VaccineImmunotherapyMedicine